198 related articles for article (PubMed ID: 30207910)
1. Limiting State Flexibility in Drug Pricing.
Bagley N; Sachs RE
N Engl J Med; 2018 Sep; 379(11):1002-1004. PubMed ID: 30207910
[No Abstract] [Full Text] [Related]
2. Will Courts Allow States to Regulate Drug Prices?
Robertson C
N Engl J Med; 2018 Sep; 379(11):1000-1002. PubMed ID: 30088965
[No Abstract] [Full Text] [Related]
3. Legal Challenges to State Drug Pricing Laws.
Lee TT; Kesselheim AS; Kapczynski A
JAMA; 2018 Mar; 319(9):865-866. PubMed ID: 29435585
[No Abstract] [Full Text] [Related]
4. States on the Front Line: Addressing America's Drug Pricing Problem.
Riley T; Lanford S
J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
[No Abstract] [Full Text] [Related]
5. Lowering Part D drug costs without direct CMS negotiations.
Sipkoff M
Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
[No Abstract] [Full Text] [Related]
6. Medicare and Medicaid programs; limits on payments for drugs--HCFA. Final rule.
Fed Regist; 1987 Jul; 52(147):28648-58. PubMed ID: 10301766
[TBL] [Abstract][Full Text] [Related]
7. States as Activists.
Buck ID
J Leg Med; 2019; 39(2):121-136. PubMed ID: 31503528
[TBL] [Abstract][Full Text] [Related]
8. Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.
Greene JA; Padula WV
N Engl J Med; 2017 Jul; 377(2):101-103. PubMed ID: 28591520
[No Abstract] [Full Text] [Related]
9. Pharmaceuticals and medical devices: cost savings. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
[No Abstract] [Full Text] [Related]
10. The war on drug--prices: states are taking up the fight to reduce prescription drug costs.
Boulard G
State Legis; 2002 Mar; 28(3):12-7. PubMed ID: 11873811
[No Abstract] [Full Text] [Related]
11. HCFA orders states to cover Clozaril costs; watchdog group urges warning on drug.
Wagner M
Mod Healthc; 1991 Jun; 21(22):14. PubMed ID: 10110762
[No Abstract] [Full Text] [Related]
12. Access to pharmaceuticals under Medicaid managed care: federal law compiled and state contracts compared.
Loza EL
Food Drug Law J; 2000; 55(3):449-76. PubMed ID: 11824469
[No Abstract] [Full Text] [Related]
13. A prescription for a modern Medicare program.
Bach PB; McClellan MB
N Engl J Med; 2005 Dec; 353(26):2733-5. PubMed ID: 16382056
[No Abstract] [Full Text] [Related]
14. Medicare Coverage of Aducanumab - Implications for State Budgets.
Sachs RE; Bagley N
N Engl J Med; 2021 Nov; 385(22):2019-2021. PubMed ID: 34797617
[No Abstract] [Full Text] [Related]
15. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
16. Will State Waivers Save, Reform, or Sabotage Obamacare?
Butler SM
JAMA; 2019 Feb; 321(5):441-442. PubMed ID: 30721284
[No Abstract] [Full Text] [Related]
17. Pharmaceuticals and Medical Devices: Cost Savings.
Steiner DJ;
Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252884
[No Abstract] [Full Text] [Related]
18. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Berry MD
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
[No Abstract] [Full Text] [Related]
19. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
[No Abstract] [Full Text] [Related]
20. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
Werling K; Abraham S; Strelec J
Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
